In this episode, Anousha is joined by Dr. Su Wang, Medical Director of the Chinese Medical Program at Cooperman Barnabas Medical Center and Medical Advisor to the Hepatitis B Foundation, along with Dr. Thomas Tu, Molecular Biologist at the Westmead Institute for Medical Research in Australia. Together, they discuss expanding hepatitis B treatment guidelines by broadening eligibility criteria, improving access, reducing loss to follow-up, and the importance of including public health and patie...
All content for B Heppy is the property of Hepatitis B Foundation and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode, Anousha is joined by Dr. Su Wang, Medical Director of the Chinese Medical Program at Cooperman Barnabas Medical Center and Medical Advisor to the Hepatitis B Foundation, along with Dr. Thomas Tu, Molecular Biologist at the Westmead Institute for Medical Research in Australia. Together, they discuss expanding hepatitis B treatment guidelines by broadening eligibility criteria, improving access, reducing loss to follow-up, and the importance of including public health and patie...
Hear from Lou Kassa, CEO of the Hepatitis B Foundation, Blumberg Institute, and Pennsylvania Biotechnology Center, and Chari Cohen, President of the Hepatitis B Foundation in an interview for our podcast as they discuss what these changes mean for our organizations and others like us. Support the show Our website: www.hepb.org Support B Heppy! Social Media: Instagram - Twitter - Facebook
B Heppy
In this episode, Anousha is joined by Dr. Su Wang, Medical Director of the Chinese Medical Program at Cooperman Barnabas Medical Center and Medical Advisor to the Hepatitis B Foundation, along with Dr. Thomas Tu, Molecular Biologist at the Westmead Institute for Medical Research in Australia. Together, they discuss expanding hepatitis B treatment guidelines by broadening eligibility criteria, improving access, reducing loss to follow-up, and the importance of including public health and patie...
